Skip to content

Wearable-Supported Exercise to Reduce Postpartum Weight

Evaluating Wearable-supported Exercise Interventions for Reducing Postpartum Weight: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07153081
Enrollment
49
Registered
2025-09-03
Start date
2020-10-20
Completion date
2021-09-12
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weight Change

Keywords

postpartum, physical activity, weight change, randomised controlled trial

Brief summary

The aim of this study is to examine the effect of walking exercise in postpartum women and to evaluate the weight management intervention by using step tracker. The following hypotheses will be tested: 1. The intervention in postpartum women would reduce the retention of weight gained during pregnancy and lower the risk factors of chronic disease. 2. Step tracker is an effective tool in encouraging the postpartum women to do more physical activity. 3. Higher physical activity is recommended for postpartum women for healthy weight lost.

Detailed description

Postpartum is an important phase in the reproductive years of women. Weight retention after childbirth can lead to chronic diseases (CD), including obesity, cardiovascular disease and other metabolic related diseases such as diabetes or high blood pressure. There are some studies suggesting that pedometer is useful to encourage women in increasing their physical activity. We propose to evaluate the effects of physical activity intervention based on wearable steps tracker and optimal weight loss for postpartum women. It will be a pilot stratified randomized intervention study on 200 postpartum women at KK Women's and Children's Hospital. Women who are above 21 years old and had given birth between 6 weeks and 6 months before will be recruited under the study. Postpartum women who physically fit to participate in moderate intensity walking are eligible to participate in the study. Women who participated in other weight management or physical activity intervention projects will be excluded from the study. Study enrolment will be done at the Specialist Outpatient Clinics for postnatal check-ups. This was 12-16 weeks randomized, single-center, unblinded intervention study (Figure 1). Participants were allocated in a 1:1 ratio to either the intervention group (Actigraphy watch) or the control group (no Actigraphy watch). All participants received the standard routine postpartum care, physical activity counselling with advice on walking and motivational messages. Randomization was done using sealed envelopes. Eligible participants had baseline measurements taken during the study enrolment and consent taking where anthropometric measurements, and blood samples were collected and various questionnaires were filled out to assess baseline demographics and lifestyle characteristics. All the participants in the intervention group received an Actigraphy watch to wear all the time except for swimming and showering. Walking advises and motivational text messages will be sent to the study participants by the research team. Data will be collected through questionnaires and clinical measurements. The questionnaires include socio-economic factors, and self-reported physical activity. Bio-physical measurements will be obtained from anthropometric measurements of participants, are collected from the participants at their follow-up time points. Objective physical activity will be collected using an Actigraphy watch.

Interventions

DEVICEActigraphy watch intervention

Participants in this group only will be given an Actigraphy watch to track their physical activity levels.

Sponsors

KK Women's and Children's Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Randomized, single-center, unblinded intervention study with a 1:! allocation ratio.

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Above 21 years old 2. Viable singleton pregnancies 3. Physically fit to participate in moderate intensity walking. 4. Term pregnancy without any sever pregnancy complications. -

Exclusion criteria

* 1\. Blood-borne disease patients (e.g. HIV, hepatitis B & C) 2. Participated in other weight management or physical activity intervention projects.

Design outcomes

Primary

MeasureTime frameDescription
Weight change at the end of the intervention at 10 weeks postpartumAt 8-12 weeks postpartum from baseline (4-8 weeks postpartum)Using measured weight in kgs
Weight change at the end of the intervention at 14 weeks postpartumAt 12 to 16 weeks postpartum from baseline ( 4-8 weeks postpartum)Using measured weight in kgs

Secondary

MeasureTime frameDescription
Change in body fat mass from baseline, 10 and 14 weeks postpartumBaseline, 10 weeks postpartum (8-12 weeks postpartum) and 14 weeks (12-16 weeks postpartum)Using body fat mass percentage measured using the bioelectrical impedance analysis scale
Change in fasting lipid profile from baseline, 10 weeks and 14 weeks postpartumBaseline, 10 weeks (8-12 week postpartum) and 14 weeks (12-16 weeks postpartum)Using fasting lipid profiles (total cholesterol, Low-density lipoprotein (LDL) cholesterol, High-density lipoprotein (HDL) cholesterol, triglycerides) of blood samples in mmol/L
Change in body mass index measures from baseline, 10 weeks postpartum and 14 weeks postpartumBaseline (4-8 weeks postpartum), 10 weeks postpartum ( 8-12 weeks postpartum) and 14 weeks postpartum (12-16 weeks postpartum)Calculating body mass index (kg/m2) using height (m) and weight (kg) measures
Change in glucose homeostasis markers from baseline at 10 weeks and 14 weeks postpartumBaseline, 10 weeks (8-12 weeks postpartum), and 14 weeks (12-16 weeks postpartum)Using fasting glucose and fasting insulin from blood samples in mmol/L
Change in waist circumference measures from baseline, 10 weeks postpartum and 14 weeks postpartumBaseline (4-8 weeks postpartum), 10 weeks (8-12 weeks postpartum) and 14 weeks (12-16 weeks postpartum)Using waist circumference measures in cm
Change in self-reported frequency of moderate to vigorous physical activity at baseline, 10 weeks and 14 weeksAt baseline, 10 weeks (8-12 weeks postpartum) and 14 weeks (12-16 weeks postpartum).Self-reported data from the International Physical Activity Questionnaire (IPAQ) to assess frequency of moderate to vigorous physical activity.
Change in self-reported duration of moderate to vigorous physical activity at baseline, 10 weeks and 14 weeksAt baseline, 10 weeks (8-12 weeks postpartum) and 14 weeks (12-16 weeks postpartum).Self-reported data from the International Physical Activity Questionnaire (IPAQ) to assess duration of moderate to vigorous physical activity..
Change in duration of objective moderate to vigorous physical activity at baseline, 10 weeks and 14 weeksBaseline, 10 weeks postpartum (8-12 weeks postpartum) and 14 weeks (12-16 weeks).MVPA will be assessed using an Actigraphy accelerometer Duration: Average daily/weekly minutes of MVPA (minutes per week).
Change in frequency of objective moderate to vigorous physical activity at baseline, 10 weeks and 14 weeksBaseline, 10 weeks postpartum (8-12 weeks postpartum) and 14 weeks (12-16 weeks).MVPA will be assessed using an Actigraphy accelerometer Frequency: Number of days per week with ≥30 minutes of MVPA (days per week).
Change in blood pressure from baseline at 10 weeks and 14 weeks postpartumAt baseline, 10 weeks (8-12 weeks postpartum) and 14 weeks (12-16 weeks postpartum)Using measured systolic and diastolic blood pressure in mm/Hg
Change in waist to hip ratio from baseline, 10 weeks and 14 weeks postpartumBaseline 6 weeks postpartum (4-8 weeks postpartum), 10 weeks postpartum (8-12 weeks postpartum) and 14 weeks postpartum (12-16 weeks postpartum).Using waist circumference and hip measures

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026